Pune, India -- (SBWIRE) -- 03/01/2019 -- Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death. Presently, it affects about 1 in 11,000 babies and about 1 in every 50 Americans is the disease carrier. On the basis of either the onset age of symptoms, SMA is classified into Type I, Type II, Type III and Type IV diseases.

Complete report on "Global Spinal Muscular Atrophy Market" with providing 4 company profiles, 5 tables and 37 figures is now available at http://www.marketreportsonline.com/782640.html.

Currently, no specific therapies for cure exist, but certain speciality drugs are expected to enter the market in the year 2019. The clinical care differs with the severity or type of the disorder category.

The global market is expected to witness a lucrative growth due the rising pharmaceuticals research and development (R&D) expenditures, increasing personal healthcare expenditure, accelerating economic growth and growing spinal muscular atrophy occurrence. The market is trending with progressing drug pipeline and high preference for gene therapy. However, there are some growth hindering factors in the market including lethargic drug approval process and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to the increasing prevalence of motor neuron disorders in the population along with high preference of genetic correction therapy and myostatin drugs.

Purchase a copy of this "Global Spinal Muscular Atrophy Market" report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=782640.

"Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)" provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Biogen Inc., Novartis International AG, Roche Holding AG and Cytokinetics, Inc are being profiled along with their respective financials and growth strategies.

Major Points from Table of Contents:

1. Market Overview
1.1 Introduction
1.2 Classification
1.3 Causes & Symptoms
1.4 Diagnosis
1.5 Treatment

2. Global Spinal Muscular Atrophy Market
2.1 Global Spinal Muscular Atrophy Market Value Forecast
2.2 Global AVXS-101 Gene Therapy Value Forecast
2.3 Global AVXS-101 Gene Therapy Value Forecast by Region
2.4 Global SRK-015 Drug Value Forecast
2.5 Global SRK-015 Drug Value Forecast by Region
2.6 Global Spinal Muscular Atrophy Incidence by Region
2.7 Global Spinal Muscular Atrophy Prevalence by Region

3. Regional Spinal Muscular Atrophy Market
3.1 The U.S. AVXS-101 Gene Therapy Value Forecast
3.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type
3.3 The U.S. SRK-015 Drug Value Forecast
3.4 The U.S. SRK-015 Drug Value Forecast by Disease Type
3.5 EU AVXS-101 Gene Therapy Value Forecast
3.6 EU AVXS-101 Gene Therapy Value Forecast by Disease Type
3.7 EU SRK-015 Drug Value Forecast
3.8 EU SRK-015 Drug Value Forecast by Disease Type

4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends and Developments
4.3 Challenges

5. Competitive Landscape
5.1 Global Spinal Muscular Atrophy Market

6. Company Profiles

Explore more Pharmaceuticals Market research as well as other newly published reports by Koncept Analytics at http://www.marketreportsonline.com/publisher/koncept-analytics-market-research.html.

About Market Reports Online
Market Reports Online is a comprehensive online library of more than 100,000 reports, in-depth market research studies on thousands of micro markets and a range of industries. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe. We offer online and offline support services to ensure your research requirements are met on time.

Contact Us:
Vishal Kalra
Tel: + 1 888 391 5441
Email: sales@marketreportsonline.com